Subcutaneous infliximab listed on PBS A subcutaneous biosimilar formulation of infliximab, Remsima SC, is listed on the PBS from 1 July. In contrast to current infliximab products that require IV infusion, Remsima SC allows subcutaneous self administration with a pre-filled pen and syringe device. The newly listed product is indicated for the treatment of moderate ...
News in Brief: Subcutaneous infliximab listed on PBS; Filgotinib induction and maintenance therapy for UC; DAA usage broadens for HCV;
1 Jul 2021